Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 74 peer-reviewed journal articles Updated
Endocrinology

Validation, Orientation, and The Name Change

At a Glance

Arginine Vasopressin Deficiency (AVP-D), formerly Central Diabetes Insipidus, is a rare disorder where the brain lacks the hormone vasopressin. The name was officially changed to prevent dangerous hospital errors, as the condition is a water-balance issue with no connection to blood sugar.

If you have spent weeks or months feeling like you are “dying of thirst,” waking up every hour to use the bathroom, and feeling completely drained of energy, your experience is valid [1]. The journey to a diagnosis for this condition is often exhausting and frightening [1][2]. You may have been told you have Central Diabetes Insipidus, but you will now hear your doctors use a new, more accurate name: Arginine Vasopressin Deficiency (AVP-D) [3][4].

Understanding Your New Diagnosis

At its simplest, Arginine Vasopressin Deficiency (AVP-D) means your brain is not making enough of a vital hormone called vasopressin (also known as antidiuretic hormone or ADH) [5][6].

Think of vasopressin as your body’s “hold your water” signal [5]. Usually, this hormone tells your kidneys to keep water in your bloodstream so you stay hydrated [7][6]. Without enough of it, your kidneys cannot concentrate your urine. Instead, they let water pour out of your body as if a faucet has been left wide open [8][9]. This leads to the hallmark symptoms of the condition:

  • Polyuria: Producing very large amounts of pale, dilute urine [10][5].
  • Polydipsia: An intense, “unquenchable” thirst for cold water [10][11].
  • Nocturia: Being forced to wake up multiple times throughout the night to urinate and drink [10][12].

A Critical Distinction: This Is Not “Sugar” Diabetes

One of the most important things for you, your family, and your medical team to understand is that AVP-D has absolutely nothing to do with blood sugar [5][1].

The older name, “Diabetes Insipidus,” shared a word with the much more common “Diabetes Mellitus” (sugar diabetes) [5][6]. This shared name has caused dangerous confusion for decades [6][13]. While Diabetes Mellitus involves insulin and blood sugar, AVP-D is a water-balance problem [5][8].

Why the Name Was Changed

In 2022 and 2023, major medical societies officially moved to the name Arginine Vasopressin Deficiency (AVP-D) to protect patients like you [3][14]. This change was driven by reports of serious, even life-threatening medical errors in hospitals [1][6].

When hospital staff see the word “Diabetes,” they often automatically think of blood sugar. In the past, this has led to:

  • Withholding water: Doctors might order a patient to have “nothing by mouth” (NPO) for a procedure, which can lead to severe, rapid dehydration in someone with AVP-D [15][16].
  • Wrong medications: There have been cases where patients with AVP-D were mistakenly given insulin because of the “diabetes” label [3][4].
  • Missed doses: Hospital staff may not realize that missing a single dose of your hormone replacement (desmopressin) is a medical emergency [1][17].

The new name, AVP-D, clearly points to the missing hormone, helping ensure that any doctor or nurse treating you understands exactly what your body needs: hormone replacement and free access to water [3][17].

Validating Your Experience

It is normal to feel overwhelmed. The constant need to drink and urinate is not just an “inconvenience”—it is a heavy burden that disrupts sleep, affects mental health, and causes significant anxiety [1][2]. Many patients report feeling “invisible” because they look healthy on the outside while struggling with extreme thirst and exhaustion on the inside [1][17].

Learning the new terminology is a powerful step in your advocacy. By using the name Arginine Vasopressin Deficiency, you are using a term that accurately describes your condition and helps keep you safe in every medical environment [3][6].

Guide Index

01

Symptoms, Warning Signs, and Adipsic Risks

Learn the symptoms of Arginine Vasopressin Deficiency (AVP-D), including extreme thirst and frequent urination. Understand hypernatremia and adipsic risks.

02

Biology, Causes, and the New Diagnostic Gold Standard

Learn the causes of Arginine Vasopressin Deficiency (AVP-D) and how it affects hydration. Understand the new hypertonic saline-stimulated copeptin test.

03

Standard of Care Treatment and Desmopressin Safety

Learn about standard desmopressin treatment for Arginine Vasopressin Deficiency (AVP-D). Understand formulation options, breakthrough dosing, and safety risks.

04

Daily Life, Hospital Hazards, and Long-Term Monitoring

Learn how to safely manage Arginine Vasopressin Deficiency (AVP-D) in daily life. Understand hospital hazards, sick day rules, and long-term health monitoring.

Common questions in this guide

Why was the name changed from Central Diabetes Insipidus to AVP-D?
The name was changed by medical societies to prevent dangerous hospital errors. Because the old name included the word 'diabetes,' hospital staff sometimes confused it with blood sugar issues, leading to severe dehydration, incorrect treatments, or missed hormone doses.
Does AVP-D have anything to do with blood sugar?
No, Arginine Vasopressin Deficiency has absolutely nothing to do with blood sugar or insulin. It is strictly a water-balance problem caused by a lack of the hormone vasopressin, which regulates how your kidneys retain water.
Why do I feel extremely thirsty all the time with AVP-D?
Without enough vasopressin, your kidneys cannot concentrate your urine and hold onto water. This causes you to lose massive amounts of fluid like an open faucet, triggering an intense, unquenchable thirst as your body desperately tries to prevent dehydration.
How can I stay safe if I am hospitalized with AVP-D?
It is critical to clearly communicate that you have Arginine Vasopressin Deficiency, a condition requiring continuous access to water and precise hormone replacement medication (desmopressin). Using the new term AVP-D helps ensure staff do not mistake it for sugar diabetes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why is the term 'Arginine Vasopressin Deficiency' more accurate for my condition than 'Central Diabetes Insipidus'?
  2. 2.How can we ensure that if I am hospitalized, the staff understands this is not a blood sugar issue and that I must have access to water?
  3. 3.Are there specific medical alert bracelets or cards you recommend that use the new AVP-D terminology?
  4. 4.What is the safest way to manage my medication to avoid both dehydration and low sodium levels?
  5. 5.How does my specific cause of AVP-D (hypothalamic or pituitary) affect my long-term care plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey.

    Atila C, Loughrey PB, Garrahy A, et al.

    The lancet. Diabetes & endocrinology 2022; (10(10)):700-709 doi:10.1016/S2213-8587(22)00219-4.

    PMID: 36007536
  2. 2

    Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls.

    Atila C, Beck J, Refardt J, et al.

    European journal of endocrinology 2024; (190(5)):354-362 doi:10.1093/ejendo/lvae040.

    PMID: 38551325
  3. 3

    Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus.

    , Arima H, Cheetham T, et al.

    European journal of endocrinology 2022; (187(5)):P1-P3 doi:10.1530/EJE-22-0751.

    PMID: 36239119
  4. 4

    Changing the name of diabetes insipidus.

    Arima H, Bichet DG, Cheetham T, et al.

    Pituitary 2022; (25(6)):777-779 doi:10.1007/s11102-022-01276-2.

    PMID: 36334185
  5. 5

    Time for change: Renaming Diabetes Insipidus to improve patient safety.

    Prentice M

    Clinical endocrinology 2018; (88(5)):625-626 doi:10.1111/cen.13578.

    PMID: 29460326
  6. 6

    Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus.

    Arima H, Cheetham T, Christ-Crain M, et al.

    Clinical endocrinology 2024; (101(5)):443-445 doi:10.1111/cen.14819.

    PMID: 36030512
  7. 7

    Arginine-stimulated copeptin in children and adolescents.

    Binder G, Weber K, Peter A, Schweizer R

    Clinical endocrinology 2023; (98(4)):548-553 doi:10.1111/cen.14880.

    PMID: 36710502
  8. 8

    Animal models of Central Diabetes Insipidus: Human relevance of acquired beyond hereditary syndromes and the role of oxytocin.

    Bernal A, Mahía J, Puerto A

    Neuroscience and biobehavioral reviews 2016; (66()):1-14.

    PMID: 27118135
  9. 9

    Diagnosis and treatment of hypernatremia.

    Tomkins M, Mc Donald D, Green D, et al.

    Best practice & research. Clinical endocrinology & metabolism 2026; (40(1)):102065 doi:10.1016/j.beem.2025.102065.

    PMID: 41203493
  10. 10

    Idiopathic Arginine Vasopressin Deficiency With an Incidental Non-functional Pituitary Microadenoma in an Elderly Diabetic Woman.

    Krishna MSV, Babu DVSP, Singh M, Madhavan S

    Cureus 2025; (17(8)):e89995 doi:10.7759/cureus.89995.

    PMID: 40951256
  11. 11

    Diabetes Insipidus: A Pragmatic Approach to Management.

    Priya G, Kalra S, Dasgupta A, Grewal E

    Cureus 2021; (13(1)):e12498 doi:10.7759/cureus.12498.

    PMID: 33425560
  12. 12

    Early central diabetes insipidus: An ominous sign in post-cardiac arrest patients.

    Chae MK, Lee JH, Lee TR, et al.

    Journal of critical care 2016; (32()):63-7.

    PMID: 26783152
  13. 13

    The combined effect of hypomagnesemia and hypokalemia inducing nephrogenic diabetes insipidus in a patient with type 1 diabetes mellitus.

    Sangey E, Chudasama K, Mwinyi A

    Clinical case reports 2021; (9(7)):e04564 doi:10.1002/ccr3.4564.

    PMID: 34322271
  14. 14

    Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus.

    , Arima H, Cheetham T, et al.

    Endocrine journal 2022; (69(11)):1281-1284 doi:10.1507/endocrj.EJ20220831.

    PMID: 36244744
  15. 15

    Adipsic diabetes insipidus.

    Kothari V, Cardona Z, Eisenberg Y

    Handbook of clinical neurology 2021; (181()):261-273 doi:10.1016/B978-0-12-820683-6.00019-1.

    PMID: 34238462
  16. 16

    A case of cerebral salt wasting syndrome in a patient with central diabetes insipidus and status epilepticus.

    Bernardi S, Zorat F, Calabrò V, et al.

    Journal of endocrinological investigation 2023; (46(6)):1275-1277 doi:10.1007/s40618-023-02053-z.

    PMID: 36932301
  17. 17

    New insights on diagnosis and treatment of AVP deficiency.

    Refardt J, Atila C, Christ-Crain M

    Reviews in endocrine & metabolic disorders 2024; (25(3)):639-649 doi:10.1007/s11154-023-09862-w.

    PMID: 38087160

This page explains Arginine Vasopressin Deficiency (AVP-D) terminology and symptoms for educational purposes only. It does not replace professional medical advice. Always consult your endocrinologist regarding your specific condition and treatment plan.

Get notified when new evidence is published on Arginine vasopressin deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.